Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study

BACKGROUND: To study safety and efficacy of apatinib in combination of radiotherapy in patients with symptomatic bony disease prostate cancer(SBPC), based on the potential synergistic antitumor activity between apatinib and Radiation Therapy (RT). PATIENTS AND METHODS: In phase I dose escalation par...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Feng, Tian, Wei, Zeng, Ming, Xia, Jianling, Hu, Honglin, Hao, Xinbao, Han, Liangfu, Liu, Hao, He, Yangke, Zhu, Xueqiang, Liang, Liang, Ao, Rui, Wei, Min, Deng, Lili, Wei, Yuquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762283/
https://www.ncbi.nlm.nih.gov/pubmed/29340015
http://dx.doi.org/10.18632/oncotarget.22719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762283/
https://www.ncbi.nlm.nih.gov/pubmed/29340015
http://dx.doi.org/10.18632/oncotarget.22719

Ejemplares similares